类风湿关节炎队列中的肺部受累:不同类型与治疗概览
该研究回顾性分析英国1129例RA患者中87例(7.7%)有肺部受累,ILD最常见(51.7%)。利妥昔单抗治疗ILD在NSIP和OP型中显示改善或稳定,肺部疾病相关死亡率约8%。
要点
- RA患者肺部受累以ILD最常见,占51.7%。
- 利妥昔单抗治疗RA-ILD在NSIP和OP型中显示改善或稳定。
- 肺部疾病相关死亡率约8%,支气管扩张者呼吸道感染住院风险高。
核心结论
- ILD是RA肺部受累最常见表现且与较高死亡率相关。
- RA常用免疫抑制药物罕见与肺毒性相关,利妥昔单抗治疗RA-ILD显示有前景的结果。
研究设计与样本
- 回顾性队列研究,纳入英国1129例RA患者中87例(7.7%)有肺部受累影像学证据者。
- 对具有肺部受累放射学证据者记录人口学、RA特征、辅助检查和治疗,采用描述性分析及Mann-Whitney U和χ2检验比较不同放射学子型。
主要发现
- 肺部疾病见于87/1129(7.7%)RA患者,97.7%在关节症状之后出现。
- 多数患者RF阳性(74/84;88.1%)和ACPA阳性(72/82;87.7%)。
- ILD为最常见模式,见于45例(51.7%)患者。
- 64例接受MTX治疗者中2例(3.1%)报告药物性肺病。
- 26例(57.8%)ILD患者使用利妥昔单抗,NSIP和OP型有改善或稳定证据。
临床怎么用
- RA患者出现肺部受累时应考虑ILD可能,尤其RF/ACPA阳性者。
- 对NSIP和OP型RA-ILD可考虑利妥昔单抗治疗。
- 合并支气管扩张的RA肺部受累患者需警惕呼吸道感染住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Lung involvement in RA has several manifestations and is a major cause of morbidity and mortality. The aim of this study was to characterize the different types of lung disease and response to treatment in a UK cohort of RA patients. METHODS: RA patients who had undergone high resolution CT scans of the lung were identified and scans reviewed. Demographic data, RA features, complementary exams and treatments were recorded for those with radiological evidence of lung involvement. Descriptive analysis was performed, and Mann-Whitney U and χ2 tests were used for comparison between different radiological subtypes. RESULTS: Lung disease was reported in 87 (7.7%) of 1129 RA patients, usually (97.7%) post-dating articular symptoms. Most patients had positive RF (74/84; 88.1%) and ACPA (72/82; 87.7%). Interstitial lung disease (ILD) was the most common pattern, reported in 45 (51.7%) patients. Drug-induced lung disease was reported in 2 of 64 (3.1%) patients treated with MTX. Rituximab was used in 26 (57.8%) patients with ILD, with evidence of disease improvement or stabilization in patients with non-specific interstitial pneumonia and organizing pneumonia. During lung disease follow-up (6.7 ± 4.1 years), 22 (25.3%) patients were admitted to hospital with respiratory infections, with 14 (63.6%) of them having underlying bronchiectasis. Lung disease-related mortality was estimated at 8%. CONCLUSION: ILD was the most prevalent manifestation of lung involvement in RA and was associated with higher mortality. Immunosuppressive drugs used in RA were rarely associated with lung toxicity, and rituximab demonstrated promising results for the treatment of RA-ILD.
引用
- Duarte AC, Porter JC, Leandro MJ, et al. The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology (Oxford). 2019. PMID: 31089697. doi:10.1093/rheumatology/kez177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。